Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group.

Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group.

Item

http://www.wikidata.org/entity/Q33385281

Q33385281

about

Recent progress in pancreatic cancer Emerging concepts in pancreatic cancer medicine: targeting the tumor stroma Curcumin AntiCancer Studies in Pancreatic Cancer Prognostic value of lymph node metastases detected during surgical exploration for pancreatic or periampullary cancer: a systematic review and meta-analysis Systemic Chemotherapy in Advanced Pancreatic Cancer Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective Local Ablative Strategies for Ductal Pancreatic Cancer (Radiofrequency Ablation, Irreversible Electroporation): A Review Current therapeutic strategies for advanced pancreatic cancer: A review for clinicians Management of pancreatic cancer in the elderly Gemcitabine Compared With Gemcitabine and S-1 Combination Therapy in Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis.Novel agents for advanced pancreatic cancer Perspectives in the treatment of pancreatic adenocarcinoma Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies Imaging and Therapy of Pancreatic Cancer with Phosphatidylserine-Targeted Nanovesicles Systemic treatment for inoperable pancreatic adenocarcinoma: review and update Pancreatic adenocarcinoma: treating a systemic disease with systemic therapy Persistent activation of pancreatic stellate cells creates a microenvironment favorable for the malignant behavior of pancreatic ductal adenocarcinoma Systemic therapies for pancreatic cancer--the role of pharmacogenetics FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer Metastatic pancreatic cancer: Is there a light at the end of the tunnel?Advances in chemotherapy for pancreatic cancer Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine Gemcitabine based combination chemotherapy in advanced pancreatic cancer-indirect comparison.Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma: JCOG0506.A randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic cancer.A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen).The use of GTX as second-line and later chemotherapy for metastatic pancreatic cancer: a retrospective analysis.Sequential FOLFOX-6 and gemcitabine for locally advanced and/or metastatic pancreatic cancer.Randomized phase II trial of S-1 and cisplatin versus gemcitabine and cisplatin in patients with advanced biliary tract adenocarcinoma.A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer.Phase II clinical trial of induction chemotherapy with fixed dose rate gemcitabine and cisplatin followed by concurrent chemoradiotherapy with capecitabine for locally advanced pancreatic cancer.A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors.Does gemcitabine-based combination therapy improve the prognosis of unresectable pancreatic cancer?Gemcitabine-oxaliplatin plus prednisolone is active in patients with castration-resistant prostate cancer for whom docetaxel-based chemotherapy failed.Frontline treatment with gemcitabine, oxaliplatin and erlotinib for the treatment of advanced or metastatic pancreatic cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG).Eltrombopag with gemcitabine-based chemotherapy in patients with advanced solid tumors: a randomized phase I study Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas.Gemcitabine fixed-dose rate infusion for the treatment of pancreatic carcinoma: a meta-analysis of randomized controlled trials.Gemcitabine plus S-1: a hopeful frontline treatment for Asian patients with unresectable advanced pancreatic cancer.Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trial.

P2860

Q24626346-CC5E8CDA-E2D1-4747-9ED0-47C1E9C565CB Q24627664-C597C4EB-4E50-4969-8D0E-8340AA66DE85 Q26738714-627C73F3-E4AA-4444-BB04-4028D402811F Q26747108-EBA1DE38-F5E4-41CC-8865-F7560D5F3689 Q26750440-3EF77468-AD7D-4F44-AA39-B811EF4E66CC Q26752368-0F3F4BA0-A9A8-4EC4-AA56-8B63FC4F6907 Q26765288-90046E15-6BD4-421F-9E12-D0C68E98E0F7 Q26767041-A3823BAE-3506-41C2-8A75-249FB51CAD13 Q26774639-77C88AD8-CF1F-450D-8E09-5A78CAF027D3 Q26786174-94BE6765-9630-4C4F-AD1D-006A060EC926 Q26787087-B3F1E49F-D279-40AA-92C1-B8EC830DED35 Q26797248-F43593A7-4F4E-410C-A6A5-D550ACB6DADC Q26799714-57B5E8BB-0BF2-4C51-A2DD-7666EBD667E8 Q26828959-0CA99BF5-5460-467A-B4E8-5844BB733481 Q26830913-B3E1F363-A668-4039-8F14-EEE149B44951 Q27008346-334AC44B-252A-44D0-BE0C-A4075E2E61B7 Q27012236-CC37B686-C8E6-47DB-A6C0-8F8208C4AC33 Q27021716-58234F43-57D4-49C0-BEAA-3905046D077E Q28075540-7867BC0B-84F1-4235-B651-3535AA9FD7B0 Q28082919-2B81A00F-BF28-49CC-B948-D73B0C149DED Q28085711-577D4B69-BF22-4877-9245-95D985E89971 Q29616728-3258282C-866D-4F48-A2C7-A16B802C5773 Q33350085-2B34B7A8-A359-490B-8EBD-AF39E049CC53 Q33388392-D9817862-A7D9-4F01-9C9F-3E97F2700908 Q33394594-D6ABCE88-46D9-4F2E-8FB6-33A137A2C1B5 Q33395577-D044B9EA-755A-459B-A643-1D158CF9BE9F Q33396763-3A4ECBD9-E918-46C3-93A1-96023A24B483 Q33400095-42127036-9726-4C5A-A6C7-35AE3087DE3D Q33401071-635FAE59-22A3-4D45-A964-25EAA46B1CE6 Q33401816-2A8DC694-C69C-4478-B289-6910E30BAA51 Q33402401-3DAAB560-9A4E-462C-83E7-F8AD8FE6D71B Q33402598-7E1396C5-DC0A-4071-867E-4D2266419A2D Q33403498-672C87AB-96FD-4EED-A782-94EF749082B6 Q33414629-62073A8E-5C24-4EE6-B2CB-825FE5BAC9BA Q33415922-E1A61288-C055-4ABA-B8D3-1411B67D5805 Q33417372-D9823682-F08B-46BB-A677-9846A8CF757D Q33418472-B8AB3788-A0CC-4B73-A0F4-72CB7227313A Q33418849-14EF9274-5134-4CF3-BDE8-1B88039FE3F0 Q33427177-5DDF9EDE-E497-4384-875B-C7B770DB6A7E Q33432931-A2CE4B27-345B-46BB-8AFC-66835B4CB1ED

P2860

Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group.

Item

http://www.wikidata.org/entity/Q33385281

description

2009 nî lūn-bûn

@nan

2009 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu